Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
Pharmaceutics · 30.12.2024 · 17 (1) · 40
DOI: 10.3390/pharmaceutics17010040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 30.12.2024. Verfasst von Xinyang Shen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Grants Committee (Hong Kong), Hong Kong Baptist University, Guangdong Science and Technology Department.
Abstract (Originalsprache)
Background/Objectives: Traditional paclitaxel therapy often results in significant side effects due to its non-specific targeting of cancer cells. Peptide aptamer–paclitaxel conjugates present a promising alternative by covalently attaching paclitaxel to a versatile peptide aptamer via a linker. Compared to antibody–paclitaxel conjugates, peptide aptamer–paclitaxel conjugates offer several advantages, including a smaller size, lower immunogenicity, improved tissue penetration, and easier engineering.
Methods
This review provides an in-depth analysis of the multifunctional peptide aptamers in these conjugates, emphasizing their structural features, therapeutic efficacy, and challenges in clinical applications.
Results
This analysis highlights the potential of peptide aptamer–paclitaxel conjugates as a novel and effective approach for targeted cancer therapy. By harnessing the unique properties of peptide aptamers, these conjugates demonstrate significant promise in improving drug delivery efficiency while reducing the adverse effects associated with traditional paclitaxel therapy.
Conclusions
The incorporation of peptide aptamers into paclitaxel conjugates offers a promising pathway for developing more efficient and targeted cancer therapies. However, further research and clinical studies are essential to fully unlock the therapeutic potential of these innovative conjugates and enhance patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
- Law Sau Fai Institute for Advancing Translational Medicine in Bone &Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China.
ORCID-Profile: Xinyang Shen, Yuan Ma, Ge Zhang
Förderung
- University Grants Committee (Hong Kong)
- Hong Kong Baptist University
- Guangdong Science and Technology Department
Zitieren
APA
Shen, X., Ma, Y., Luo, H., Abdullah, R., Pan, Y., Zhang, Y., Zhong, C., Zhang, B., & Zhang, G. (2024). Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy. Pharmaceutics, 17(1), 40. https://doi.org/10.3390/pharmaceutics17010040
Vancouver
Shen X, Ma Y, Luo H, Abdullah R, Pan Y, Zhang Y, et al. Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy. Pharmaceutics. 2024;17(1):40. doi:10.3390/pharmaceutics17010040
BibTeX
@article{Shen2024,
author = {Shen, Xinyang and Ma, Yuan and Luo, Hang and Abdullah, Razack and Pan, Yufei and Zhang, Yihao and Zhong, Chuanxin and Zhang, Baoting and Zhang, Ge},
title = {Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy},
journal = {Pharmaceutics},
year = {2024},
volume = {17},
number = {1},
pages = {40},
doi = {10.3390/pharmaceutics17010040}
}
EUVIMED